Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: A double-blind placebo-controlled study

A fall in nocturnal plasma melatonin occurs in patients with cluster headache, suggesting that melatonin may play a role in the promotion of attacks. During a cluster period, we administered melatonin to 20 cluster headache patients (2 primary chronic, 18 episodic) in a double-blind placebo-controlled study of oral melatonin 10 mg ( n=10) or placebo ( n=10) for 14 days taken in a single evening dose. Headache frequency was significantly reduced (ANOVA, p<0.03) and there were strong trends towards reduced analgesic consumption (ANOVA, p<0.06) in the treatment group. Five of the 10 treated patients were responders whose attack frequency declined 3-5 days after treatment, and they experienced no further attacks until melatonin was discontinued. The chronic cluster patients did not respond. No patient in the placebo group responded. There were no side effects in either group. Although the response rate is low, melatonin may be suitable for cluster headache prophylaxis in some patients, particularly those who cannot tolerate other drugs.

Download Full-text

A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently

Bipolar Disorders ◽

10.1111/j.1399-5618.2009.00761.x ◽

2009 ◽

Vol 11 (8) ◽

pp. 827-839 ◽

Cited By ~ 73

Author(s):

Wayne Macfadden ◽

Larry Alphs ◽

J Thomas Haskins ◽

Norris Turner ◽

Ibrahim Turkoz ◽

...

Keyword(s):

Maintenance Treatment ◽

Controlled Study ◽

Double Blind ◽

Bipolar I Disorder ◽

Double Blind Placebo ◽

Long Acting

Download Full-text

P3-029: The ASAP Study: Alzheimer's Symptoms are Preventable-A Five-Year, Double Blind, Placebo Controlled Study of Long-Acting Salsalate in Subjects Age 65 and Less Who Carry One or two Copies of APOE4 Allele Along with Parental History of Dementia

Alzheimer s & Dementia ◽

10.1016/j.jalz.2016.06.1686 ◽

2016 ◽

Vol 12 ◽

pp. P828-P828

Author(s):

Joel Steven Ross ◽

Mark Ornstein

Keyword(s):

Controlled Study ◽

Double Blind ◽

Parental History ◽

Double Blind Placebo ◽

Apoe4 Allele ◽

History Of ◽

Long Acting

Download Full-text

Comparison of Propranolol LA 80 mg and Propranolol LA 160 mg in Migraine Prophylaxis: A Placebo Controlled Study

Cephalalgia ◽

10.1046/j.1468-2982.1993.1302128.x ◽

1993 ◽

Vol 13 (2) ◽

pp. 128-131 ◽

Cited By ~ 15

Author(s):

Hisham K Al-Qassab ◽

Leslie J Findley

Keyword(s):

Side Effects ◽

Migraine Prophylaxis ◽

Controlled Study ◽

Headache Frequency ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Headache Severity ◽

Negative Effect ◽

Long Acting

Thirty patients with severe classical and common migraine participated in a double-blind placebo-con-trolled cross-over study of migraine prophylaxis with propranolol LA (long-acting) 80 mg once daily, or propranolol LA 160 mg once daily or placebo. Each treatment was given for two months. There were no significant differences between the three treatment periods in headache frequency, headache severity, nausea frequency or severity. There was a non-significant trend for reduced duration of headache with the two doses of propranolol. The possible reasons for this negative effect are discussed. The safety of propranolol and its lack of serious side effects were demonstrated.

Download Full-text